INVITED REVIEW
Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis

Yuval Dor, Rinnat Porat, and Eli Keshet

Department of Molecular Biology, The Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
VEGF AS A MEDIATOR...
VEGF AS A MEDIATOR...
VEGF AND VESSEL MATURATION
PATHOLOGICAL AND THERAPEUTIC...
REFERENCES

Development of microvascular networks is set to meet the metabolic requirements of the tissue they perfuse. Accordingly, impairment of oxygen homeostasis, either due to increased oxygen consumption or as a result of blood vessel occlusion, triggers compensatory neovascularization. This feedback reaction is mediated by a hypoxia- and hypoglycemia-induced vascular endothelial growth factor (VEGF). VEGF accumulates under stress as a result of increased hypoxia-inducible factor-1alpha -mediated transcription, stabilization of the mRNA, and the function of a hypoxia-refractory internal ribosome entry site within its 5'-untranslated region. Matching of vascular density to the metabolic needs of the tissue may include a process of hyperoxia-induced vessel regression. Thus newly formed vascular networks may undergo a natural process of vascular pruning that takes place whenever VEGF, acting as a vascular survival factor, is downregulated below the level required to sustain immature vessels. Immature vessels are particularly vulnerable and are selectively obliterated upon withdrawal of VEGF. The plasticity window for vessel regression is determined by a delay in the recruitment of periendothelial cells to the preformed endothelial plexus. Thus fine-tuning of microvascular density takes place mostly in the newly formed plexus, but the mature system is refractory to episodic changes in tissue oxygenation. These regulatory links may malfunction in certain pathological settings.

angiogenesis; hypoxia; hyperoxia; vessel regression


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
VEGF AS A MEDIATOR...
VEGF AS A MEDIATOR...
VEGF AND VESSEL MATURATION
PATHOLOGICAL AND THERAPEUTIC...
REFERENCES

ANGIOGENESIS, defined as the formation of new blood vessels as extensions of existing vessels, in the adult, healthy organism is limited to certain organs (e.g., the female reproductive system). Remarkably, however, extensive angiogenic responses are elicited under circumstances in which oxygen homeostasis is perturbed. Thus a sustained increase in oxygen consumption or a functional impairment of existing vasculature, both resulting in insufficient perfusion, triggers neovascularization. It has long been recognized that that the driving force of compensatory angiogenesis is the condition of oxygen and nutrient deprivation. The ischemic tissue detects insufficient oxygen (hypoxia) or insufficient glucose (hypoglycemia) and responds by inducing locally the production of angiogenic factors that recruit new blood vessels to the ischemic area. The findings that the potent angiogenic factor vascular endothelial growth factor (VEGF) is induced by hypoxia and, independently, by hypoglycemia (45, 60, 64) have suggested VEGF as the molecular link in this positive feedback response. This thesis was subsequently corroborated and extended by intensive research that is reviewed below.

Adjusting the finite vascular density to match the metabolic requirements of the tissue also includes the capacity to eliminate surplus blood vessels under conditions in which oxygen supply exceeds the metabolic requirements of the tissue. Development of the retina vasculature is a prime example of a process by which a new vascular plexus is initially formed in exuberance and subsequently trimmed in an oxygen-dependent manner (4). Pruning surplus vascular loops is regarded as "economical" because it eliminates the need for long-term maintenance of unnecessary vessels. Until recently, however, the molecular mechanism underlying vascular pruning has remained unknown. Recent findings showing that VEGF functions also as a vascular survival factor essential to sustain newly formed blood vessels (2) have suggested that the levels of available VEGF might also determine the degree of vascular pruning. Studies reviewed below support the thesis that hyperoxia-induced suppression of VEGF indeed triggers the regression of surplus vessels.

It appears, therefore, that VEGF can promote both the "up-" and "downsides" in the vascular responses to imbalances in oxygenation. According to this unified view, a range of oxygen concentrations may result in the production of an "angiogenic dose," a "maintenance dose," or a "submaintenance dose" of VEGF. The review also discusses pathological circumstances of hypoxia-driven neovascularization and pathological circumstances of excessive vascular pruning.

Formation of new vascular networks by the angiogenic mode is characterized by initial formation of an endothelial cell plexus and is followed by the recruitment of periendothelial cells, namely, pericytes and smooth muscle cells. The acquisition of a periendothelial cell coating is thought to represent an important step in vessel maturation. Pertinent to the scope of this review is the thesis that "immature" and "mature" vascular networks differ with respect to their dependence on VEGF for survival. Specifically, it has been shown that immature vessels regress upon VEGF withdrawal, whereas mature vessels (operatively identified as vessels covered by periendothelial cells) appear independent of VEGF (6, 7). The existence of a transient developmental stage in which a newly formed vascular network can be remodeled to optimize perfusion rates, on one hand, and the loss of this capability at later stages, on the other hand, assures both sufficient plasticity during the formative stage and long-term stability against episodic changes in the levels of tissue oxygenation. Finally, the potential implications of enforcing the regression of immature tumor vessels are discussed.


    VEGF AS A MEDIATOR OF HYPOXIA-INDUCED ANGIOGENESIS
TOP
ABSTRACT
INTRODUCTION
VEGF AS A MEDIATOR...
VEGF AS A MEDIATOR...
VEGF AND VESSEL MATURATION
PATHOLOGICAL AND THERAPEUTIC...
REFERENCES

Physiological and pathological circumstances of hypoxia-induced angiogenesis. Hypoxia-induced angiogenesis is primarily an adaptive physiological response to either an increase in tissue mass (e.g., neovascularization accompanying mass increase in a muscle tissue) or a chronic increase in working load associated with elevated oxygen consumption. An increase in neuronal activity, in particular, is associated with increased oxygen consumption and usually leads to an immediate response of increased blood flow, but an intense chronic increase in neuronal activity is often accompanied by neovascularization manifested in increased vascular density (9).

At least some processes of developmental angiogenesis are driven by hypoxia. A developmental increase in oxygen consumption during organogenesis may result in a mild, subpathological level of hypoxia ("physiological hypoxia"), which may serve as a trigger for microvascular expansion. In the retina, increased oxygen consumption at the onset of photoreceptor activity results in insufficient perfusion of the overlying ganglion and inner cell layers. Hypoxia is then "sensed" by strategically located glial cells that upregulate and secrete VEGF (63). It is unlikely, however, that oxygen plays a role in stereospecific patterning of major vessels that are formed by the vasculogenic mode (49). A recent study has shown that physiological hypoxia is also essential for proper development of hematopoietic lineages (1).

In the adult, observations regarding dynamic changes in vasa vasorum attest to hypoxia-induced vascular remodeling: capillaries further penetrate the muscular walls of thick vessels whenever a gap remains in the range of oxygen diffusion from the luminal and adventitial sides. Thus vasa vasorum sprouts penetrate deeper when luminal flow is compromised (e.g., at sites of atherosclerosis) and regress when flow is improved (e.g., with regression of atherosclerosis) (71, 73).

Regional ischemia resulting from occlusion of blood vessels is conducive for the development of collateral blood vessels. Unlike the previous cases, collateral development is not restricted to formation of microvessels, and larger vessels are also formed. Formation of a collateral network seems to include both "classic" angiogenesis, i.e., formation of new vascular sprouts, and the recruitment of preexisting vessels. The latter still requires the formation of new connections through vascular fusions (62, 70). A third mechanism playing an important role in collateral formation is arteriogenesis (55). Arteriogenesis is distinguished by the enforcement and increase in diameter of existing vessels through interstitial growth. While it is feasible that interstitial vessel growth is also mediated by ischemia-induced factors, recent studies have highlighted the role of flow-regulated factors in arteriogenesis. According to this view, an increase in shear stress due to the diversion of flow to these vessels induces activities, other than VEGF, that directly or indirectly (e.g., through the induction of macrophage chemoattractants) lead to endothelial cell proliferation (10, 55).

The adaptation of skeletal muscle in humans to endurance-type training is associated with increased capillary density and increased capillary-to-fiber ratio. Recent studies have shown that VEGF (but not basic fibroblast growth factor) is upregulated in human muscle by a single bout of dynamic exercise, thus supporting the concept that VEGF is involved in exercise-induced skeletal muscle angiogenesis (29, 47). Furthermore, a negative feedback mechanism was suggested by showing that exercise adaptation attenuates VEGF gene expression in human skeletal muscle (48).

Tissue ischemia usually develops as a result of vascular injury in wounds. Hence, ischemia-driven angiogenesis is a major factor in neovascularization associated with wound healing. Indeed, a hypoxic tissue gradient is mandatory for wound-healing angiogenesis, and when the hypoxic gradient is destroyed, capillary growth ceases (35). Macrophages known to be a major source of angiogenic stimuli, including VEGF (34), are preferentially recruited to hypoxic regions of the wound (31).

Ischemia-induced angiogenesis is also a major component of tumor neovascularization. Tumor angiogenesis has been traditionally viewed as the consequence of an "angiogenic switch," i.e., a genetic event that endows the tumor with the ability to recruit blood vessels from the neighboring tissue. However, tumor cells, like their normal counterparts, are able to "sense" ischemia and respond with increased angiogenesis. Therefore, stress-induced angiogenesis is an important component of tumor neovascularization, independent of angiogenic activities produced by a genetic switch. Recent studies employing tumorigenic cells deficient in their hypoxia responsiveness evaluated the relative contribution of environmental hypoxic stress to the overall angiogenic output of the tumor: hypoxia-inducible factor (HIF)-1alpha -deficient embryonic stem cells, as well as a mouse hepatoma line deficient in the HIF-1beta subunit, were xenografted into nude mice and assayed for tumor growth and angiogenesis (11, 41, 51). HIF-1-deficient tumors showed a significant reduction in vascularity. Notably, HIF-1alpha -deficient tumors were deficient in medium- and large-sized vessels, while capillary density was comparable with that of the corresponding wild-type tumors. This deficit in blood vessels was reflected in a 50% reduction in blood flow rate and a 90% reduction in overall oxygen delivery to HIF-1alpha -null tumors. These results attest to the key role of hypoxia-induced angiogenesis as a major contributor to tumor neovascularization. However, recent studies employing a tumorigenic cell line nullizygous for HIF-1alpha have shown that, despite differences in VEGF expression (whose expression is greatly compromised in HIF-1-null tumors), vascular density is similar in wild-type and HIF-1-null tumors, suggesting that the negative effect on tumor growth is not due to deficient vascularization (52). Certain pathological conditions, exemplified by different forms of retinopathy, are caused by an exaggerated angiogenesis in response to ischemia. Functional deterioration of retinal vessels in the case of proliferative diabetic retinopathy, obliteration of immature retinal vessels in the case of retinopathy of prematurity (ROP), and vascular occlusions in the case of a central retinal vein occlusion all lead to a severe retinal ischemia. Severe retinal ischemia elicits, in turn, a compensatory angiogenic response that is, however, vastly exaggerated (3, 43). In these pathologies vascular growth is excessive, vessels are abnormally leaky, and vessels that are otherwise confined to the retina grow into the virtuous and inflict retina detachment. This pathogenic sequela renders ischemia-driven angiogenesis the leading cause of blindness worldwide.

Molecular mechanisms of hypoxic VEGF regulation. The pivotal role that VEGF plays in mediating both vasculogenic and angiogenic modes of blood vessel formation is reflected by the multiple regulations of VEGF expression. Notably, various cytokines and growth factors may regulate VEGF mRNA and protein expression, including endothelial growth factor, transforming growth factor (TGF)-beta , keratinocyte growth factor, interleukin (IL)-1alpha , IL-6, and insulin-like growth factor-1 (for a recent review, see Ref. 20 and references therein). In addition, VEGF is also subjected to hormonal regulations, including regulation by thyroid-stimulating hormone (63) and a tight regulation by estrogens during cyclic developmental of ovarian follicles and corpus luteum (22). A detailed account of various controls of VEGF expression, however, is beyond the scope of this review, which focuses on its regulation by oxygen.

In addition to hypoxia, acute glucose deprivation, an accompaniment of vascular insufficiency, also leads to VEGF induction (61). Multicell spheroids were used to simulate a clonal cell population in which gradients of oxygen, glucose, and other nutrients create a continuum of different microenvironments. Results have uncovered a complex combinatorial relationship of oxygen and glucose deficiencies conducive for VEGF induction. Importantly, VEGF is not induced in overstressed, metabolically compromised cells (61). These findings suggest that the magnitude of the angiogenic response may depend on the nature of the insult (e.g., ischemia resulting from an abrupt vs. gradual occlusion of a major vessel). Different forms of stress may also account for the observation that the degree of collateral growth is highly variable among individuals. Another factor that might account for individual differences in responsiveness to ischemic insults is a different ability to upregulate HIF-1 in response to hypoxia (59). Ischemia is a frequent accompaniment of aging, and elderly people often show a reduced ability to mount an angiogenic response compared with young individuals (e.g., neovascularization of hypoxic wounds). A recent study has shown that an age-dependent deficit in VEGF expression is associated with a reduced HIF-1 activity, thus providing a mechanistic explanation for this phenomenon (50).

Transcriptional regulation of VEGF is mediated by the transcription factor HIF-1. The nature of the "oxygen sensor," putative pathways of signal transduction converging on HIF-1, and the repertoire of HIF-1 target genes have been extensively discussed in excellent recent reviews (see, e.g., Refs. 56, 57, and 74). Briefly, HIF-1 protein accumulates under conditions of hypoxia, because of stabilization of the otherwise extremely labile protein (30). VEGF shares with other HIF-1-regulated genes, notably genes whose products are involved in systemic (e.g., erythropoietin), local (e.g., inducible nitric oxide synthase), and cellular (e.g., glycolytic enzymes) responses to hypoxia, consensus HIF-1 binding sequences in its promoter. Inhibition of HIF-1 binding, either through mutation of the binding site or by preventing heterodimerization of HIF-1 with its obligatory partner aryl hydrocarbon receptor nuclear translocator, abolishes a significant fraction (but not all) of hypoxia-inducible VEGF (11, 24, 72).

Another level of regulation is hypoxia- and hypoglycemia-induced stabilization of VEGF mRNA (32, 58, 65). The intrinsically short half-life of VEGF mRNA (~30 min) is significantly extended under stress, presumably through hypoxia-augmented binding of yet unidentified protein(s) to its 3'-untranslated region (37, 38).

VEGF is also subjected to a translational regulation, which secures efficient production of the protein even under unfavorable stress conditions. The requirement for translational regulation of VEGF is imposed by the cumbersome structure of the 5'-untranslated region, which is incompatible with efficient translation by ribosomal scanning, and by the physiological requirement for maximal VEGF production under conditions of hypoxia in which overall protein synthesis is compromised. With the use of bicistronic reporter gene constructs, it has been shown that the 1,014-bp-long 5'-untranslated region of VEGF contains a functional internal ribosome entry site. Efficient cap-independent translation is maintained under hypoxia, thereby allowing maximal translation under severe hypoxia (66).


    VEGF AS A MEDIATOR OF VASCULAR PRUNING
TOP
ABSTRACT
INTRODUCTION
VEGF AS A MEDIATOR...
VEGF AS A MEDIATOR...
VEGF AND VESSEL MATURATION
PATHOLOGICAL AND THERAPEUTIC...
REFERENCES

As discussed above, the downside in the process aimed to match vascular density to changes in oxygen supply is hyperoxia-induced vascular regression. Vascular pruning takes place after the initiation of flow through the newly formed vascular network and is thought to result from excess oxygen reaching the tissue. In fact, the exposure of an immature vascular system to an experimental hyperoxia leads to an exaggerated vascular pruning and extensive elimination of many vascular loops. Notably, hyperoxia-induced obliteration of newly formed blood vessels in the retina of the premature newborn is the underlying cause of ROP. A rodent model of ROP was used to show that regression of retinal capillaries in neonatal rats exposed to high oxygen is preceded by a shutoff of VEGF production, leading in turn to selective apoptosis of endothelial cells (2). These findings have prompted the proposition that VEGF functions as a vascular survival factor and that its hyperoxic downregulation to a level lower than that required to sustain immature vessels results in their regression. This proposition was subsequently established by showing that injection of VEGF at the onset of experimental hyperoxia prevents apoptotic death of endothelial cells and rescues the retinal vasculature (2).

The most critical factor in pathogenesis of ROP, also recapitulated in the ROP rodent model, is the timing of the hyperoxic insult. Thus the incidence of ROP drops precipitously when the premature baby is placed in hyperoxia at a late gestational age (25) and does not develop in the rodent model if the insult is given later than 10 days after birth. It appears, therefore, that VEGF is critical for the survival of "immature/remodeling" blood vessels and that independence from VEGF is a molecular hallmark of maturation. Studies summarized below have shown that the recruitment of periendothelial cells to the preformed endothelial plexus renders newly formed vessels refractory to VEGF depletion, in general, and to hyperoxic insults, in particular.


    VEGF AND VESSEL MATURATION
TOP
ABSTRACT
INTRODUCTION
VEGF AS A MEDIATOR...
VEGF AS A MEDIATOR...
VEGF AND VESSEL MATURATION
PATHOLOGICAL AND THERAPEUTIC...
REFERENCES

Several studies have suggested that association with mural cells is critical for proper vascular development and maintenance (for reviews, see Refs. 5 and 15). Pericytes are cells surrounded by basement membrane and intimately associated with endothelial cells in the microvasculature. Pericytes express alpha -smooth muscle actin (alpha -SMA) and thus have been implied to have a contractile function. In vitro studies have highlighted the possible role of pericytes and smooth muscle cells in regulating endothelial cell proliferation via secretion of inhibitory growth factors such as TGF-beta (44) and inhibition of migration (54). Supporting data for the regulation of the endothelial cell network by pericytes is the observation that pericyte dropout precedes proliferative retinopathy in diabetic patients (64). A role for mural cells in maintaining vascular integrity was suggested by a number of gene knockout studies. This includes disruption of the genes encoding the endothelial cell-specific receptors Tie-1 and Tie-2 (17, 46, 53), the Tie-2 ligand angiopoietin-1 (Ang-1) (69), the tissue factor system (13), and the platelet-derived growth factor B (PDGF-B)/PDGF-beta receptor system (36, 39). Mice deficient in these genes show a hemorrhaging phenotype often associated with a reduced number of alpha -SMA-positive perivascular cells. Studies of postnatal remodeling of the retina vasculature have shown that pericyte recruitment proceeds by out-migration from arterioles and that coverage of primary and smaller branches lags many days behind formation of the endothelial plexus. Interestingly, pericyte coverage is also enhanced by VEGF itself via an unknown mechanism (7). In vitro studies support a direct role for VEGF in pericyte recruitment by showing that cultured smooth muscle cells express VEGF receptors and that VEGF acts as a smooth muscle cell chemoattractant (28). The transient existence of a pericyte-free endothelial plexus in the retina coincides temporally and spatially with the process of hyperoxia-induced vascular pruning. Thus the acquisition of a pericyte coating marks the end of this plasticity window in the retina and stabilizes its vasculature. Analysis of angiogenic and regressive cycles in the corpus luteum has led to the conclusion that endothelial cell survival in midstage corpus luteum is correlated with the microvessel maturation index and that induction of blood vessel regression during luteolysis is characterized by the downregulation of VEGF and the upregulation of Ang-2 (26). Pericytes are thought to provide nearby endothelial cells with alternative survival factors, perhaps by depositing those factors in the shared extracellular matrix.

On the basis of these findings, the following scenario is envisaged (Fig. 1): a developmental increase in oxygen consumption and a resultant physiological hypoxia are the driving forces for VEGF-mediated neovascularization. However, only after the onset of flow through the newly made vasculature can the system be "checked" with respect to the adequacy/surplus of oxygen reaching the tissue. Therefore, there is a physiological advantage to maintain the option of vascular pruning for a certain time after the formation of the initial plexus. The end of the plasticity window, distinguished by the acquisition of a pericyte coating, prevents deleterious vessel regression due to transient fluctuations in tissue oxygen that may occasionally take place in the mature animal.


View larger version (52K):
[in this window]
[in a new window]
 
Fig. 1.   Schematic illustration of 3 sequential processes acting in concert to match microvascular density according to the level of tissue oxygenation. Hypoxia-driven neovascularization is mediated by high levels of vascular endothelial growth factor (VEGF). Hyperoxia-induced vessel regression results from suppression of VEGF expression. Vessel maturation renders the system VEGF independent. N, normoxic oxygen level.

This putative scenario has been documented mostly for the retina system, and it remains to be determined whether it can be generalized to include additional organs. Vascular remodeling in the postnatal brain, for example, involves vessel rarefaction (19) but may take place after the acquisition of a pericyte coating. A reduced density of arterioles and capillaries is an important common characteristic of various vascular beds in many forms of hypertension, but the mechanism of vessel rarefaction in hypertension is not clear (for review, see Ref. 68). Oxygen-induced vessel regression represents only one form of vessel regression, namely, vascular trimming taking place in temporal proximity to neovascularization. From a mechanistic point of view, it is most likely that developmentally programmed regression of fully mature functioning vascular networks (e.g., regression of hyaloid vessels in the eye) is not triggered by changes in oxygen.


    PATHOLOGICAL AND THERAPEUTIC IMPLICATIONS
TOP
ABSTRACT
INTRODUCTION
VEGF AS A MEDIATOR...
VEGF AS A MEDIATOR...
VEGF AND VESSEL MATURATION
PATHOLOGICAL AND THERAPEUTIC...
REFERENCES

What might be the implications of the otherwise physiological oxygen-VEGF-blood vessel connection in disease development and treatment?

The possibility that hypoxic episodes during pregnancy may contribute to congenital defects in cardiovascular development needs to be considered. Development of the cardiovascular system is exquisitely dependent on normal levels and appropriately timed expression of VEGF (12, 16, 21). Yet, VEGF is also robustly induced by environmental stresses. Hypoxic insults during embryogenesis, therefore, are likely to transiently induce high levels of VEGF, superimposed on the developmentally regulated program of expression, and, hence, contribute to congenital heart defects. The etiology of congenital heart defects (CHD) is thought to be multifactorial, involving interplay between genetic and environmental factors. The nature and mechanisms of action of the environmental insults have remained largely unknown, but the importance of embryonic hypoxia as a cardiac teratogen has long been recognized. Congenital cardiac anomalies are more prevalent at high altitude (42), and a number of studies have shown that experimental prenatal hypoxia in rats, mice, and chicks greatly increases the frequency of a host of cardiac malformations (see, e.g., Refs. 14 and 27). To date, however, the mechanism by which prenatal hypoxia contributes to CHD has not been explored.

As noted above, imbalances in both hypoxia-induced angiogenesis and hyperoxia-induced pruning are the underlying causes in the pathogenesis of major blindness-causing diseases. Specifically, pathogenesis of the different forms of retinopathy, irrespective of their etiological cause, converges at the stage of the highly ischemic retina. Already more than 50 years ago, Michaelson (43) suggested the existence of a hypoxia-inducible angiogenic factor that is responsible for the exaggerated, pathological angiogenic response. Many years later, this hypothetical factor was identified as VEGF. Current therapeutic approaches include attempts to block VEGF production or signaling as well as the inhibition of downstream events in the angiogenic cascade. In the case of ROP, which is initiated by excessive vascular pruning, the findings that administered VEGF (in its capacity as a vascular survival factor) can prevent excessive pruning have suggested a new modality for ROP prevention (2).

The prospects of therapeutic augmentation of blood delivery through enhancement of collateral formation are exciting. Preclinical studies have shown that collaterals can be induced in the ischemic limb or heart through direct administration of angiogenic factors, primarily VEGF, but also by members of the fibroblast growth factor family. Also, different modes of angiogenic factor delivery have been used successfully, including DNA-mediated gene transfer (for review, see Ref. 40). These encouraging results have prompted clinical trials that are currently underway. Induction of compensatory angiogenesis could also be attempted at different points along the hypoxia-VEGF axis upstream of VEGF. For example, HIF-1alpha (or HIF-1alpha chimeras), which coordinates multiple homeostatic responses to hypoxia, including the induction of VEGF, is likely to improve the perfusion of an ischemic tissue. In principle, it might be possible to pharmacologically induce the transduction system connecting the oxygen sensor to upregulated target genes. Our very poor understanding of the molecular nature of the oxygen sensor, however, has hampered this option.

In oncology, newly gained insights regarding the roles of hypoxia and VEGF in tumor biology have suggested some new approaches to keep tumor growth in check and possibly also to induce tumor regression. Preclinical studies have employed different strategies to antagonize VEGF action, including the use of anti-VEGF neutralizing antibodies, the use of soluble versions of VEGF receptors 1 and 2 acting in a dominant-negative fashion, and the design of inhibitors of the VEGF-R2 tyrosine kinase (23, 33). Encouraging positive results, manifested by a significant inhibition of tumor growth and evidence for a reduced vasculature, led to the advancement of few drugs into clinical trials. The fact that tumors generally maintain the capacity to upregulate VEGF in response to hypoxia suggests that, irrespective of the antiangiogenic method employed, vascular collapse is bound to result in extensive hypoxia that, in turn, will elicit a second angiogenic wave mediated by VEGF. Thus antagonizing VEGF might also take care of an anticipated second angiogenic wave.

To what extent is the dependence of immature blood vessels on VEGF for survival relevant to growing tumors? Tumor expansion is associated with a continuous formation of new vessels and remodeling of existing vessels. Thus, unlike blood vessels in the adjacent normal tissue, a significant fraction of tumor vessels are in a relative state of immaturity (6, 18). Immature vessels frequently found in tumors might represent a subset of vulnerable vessels requiring the continuous presence of VEGF. In fact, with the use of a tetracycline-regulated VEGF expression system in xenografted C6 glioma cells, it was shown that shutting off VEGF production leads to detachment of endothelial cells from the walls of, specifically, immature vessels and their subsequent death by apoptosis. Vascular collapse then led to hemorrhages and extensive tumor necrosis (8). Furthermore, it has been shown that early regression of vessels as a consequence of androgen-ablation therapy in prostate carcinoma is due to suppression of androgen-regulated VEGF-production (6). The dual action of VEGF as an angiogenic factor as well as a vascular survival factor may provide a mechanistic explanation to the thesis that VEGF deprivation might lead not only to inhibition of further angiogenesis but also to regression of preformed tumor vessels.


    FOOTNOTES

Address for reprint requests and other correspondence: E. Keshet, Dept. of Molecular Biology, The Hebrew Univ.-Hadassah Medical School, Jerusalem 91120, Israel (E-mail: keshet{at}cc.huji.ac.il).


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
VEGF AS A MEDIATOR...
VEGF AS A MEDIATOR...
VEGF AND VESSEL MATURATION
PATHOLOGICAL AND THERAPEUTIC...
REFERENCES

1.   Adelman, DM, Maltepe A, and Simon MC. Multilineage embryonic hematopoiesis requires hypoxic ARNT activity. Genes Dev 13: 2478-2483, 1999[Abstract/Free Full Text].

2.   Alon, T, Hemo I, Itin A, Pe'er J, Stone J, and Keshet E. VEGF acts as a survival factor for newly-formed retinal vessels: implications for retinopathy of prematurity. Nat Med 1: 1024-1028, 1995[ISI][Medline].

3.   Ashton, N. Retinal vascularization in health and disease. Am J Ophthalmol 44: 7-17, 1957[ISI].

4.   Ashton, N. Oxygen and the growth and development of retinal vessels. Am J Ophthalmol 62: 412-435, 1966[ISI][Medline].

5.   Beck, L, and D'Amore PA. Vascular development: cellular and molecular regulation. FASEB J 11: 365-373, 1997[Abstract/Free Full Text].

6.   Benjamin, LE, Golijanin D, Itin A, Pode D, and Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103: 159-165, 1999[Abstract/Free Full Text].

7.   Benjamin, LE, Hemo I, and Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125: 1591-1598, 1998[Abstract/Free Full Text].

8.   Benjamin, LE, and Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 94: 8761-8766, 1997[Abstract/Free Full Text].

9.   Black, JE, Sirevaag AM, and Greenough WT. Complex experience promotes capillary formation in young rat visual cortex. Neurosci Lett 83: 351-355, 1987[ISI][Medline].

10.   Buschmann, I, and Schaper W. The pathophysiology of collateral circulation. J Pathol 190: 338-342, 2000[ISI][Medline].

11.   Carmeliet, P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, and Keshet E. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394: 485-490, 1998[ISI][Medline].

12.   Carmeliet, P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, and Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435-439, 1996[ISI][Medline].

13.   Carmeliet, P, Mackman N, Moons L, Luther T, Gressens P, Van Vlaenderen I, Demunck H, Kasper M, Breier G, Evrard P, Muller M, Risau W, Edgington T, and Collen D. Role of tissue factor in embryonic blood vessel development. Nature 383: 73-75, 1996[ISI][Medline].

14.   Clemmer, TP, and Telford IR. Abnormal development of the rat heart during prenatal hypoxic stress. Proc Soc Exp Biol Med 121: 800-803, 1966.

15.   Diaz Flores, L, Gutierrez R, Varela H, Rancel N, and Valladares F. Microvascular pericytes: a review of their morphological and functional characteristics. Histol Histopathol 6: 269-286, 1991[ISI][Medline].

16.   Drake, CJ, and Little CD. Exogenous vascular endothelial growth factor induces malformed and hyperfused vessels during embryonic neovascularization. Proc Natl Acad Sci USA 92: 7657-7661, 1995[Abstract].

17.   Dumont, DJ, Gradwohl G, Fong GH, Puri MC, Gertsenstein M, Auerbach A, and Breitman ML. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 8: 1897-1909, 1994[Abstract].

18.   Eberhard, A, Kahlert S, Goede V, Hemmerlein B, Plate KH, and Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 60: 1388-1393, 2000[Abstract/Free Full Text].

19.   Feher, G, Schutle ML, Weigle CG, Kampine JP, and Hudetz AG. Postnatal remodeling of the leptomeningeal vascular network as assessed by intravital fluorescence video-microscopy in the rat. Brain Res Dev Brain Res 91: 209-217, 1996[ISI][Medline].

20.   Ferrara, N. The role of vascular endothelial growth factor in angiogenesis. In: Angiogenesis in Health and Disease, edited by Rubanyi GM.. New York: Marcel Dekker, 2000, p. 47-74.

21.   Ferrara, N, Carver Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell Braxton L, Hillan KJ, and Moore MW. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439-442, 1996[ISI][Medline].

22.   Ferrara, N, Chen H, Davis-Smyth T, Gerber H-P, Nguyen T-N, Peers D, Chisholm V, Hillan KJ, and Schwall RH. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 4: 336-340, 1998[ISI][Medline].

23.   Fong, TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, and McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59: 99-106, 1999[Abstract/Free Full Text].

24.   Forsythe, JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, and Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604-4613, 1996[Abstract].

25.   Gibson, DL, Sheps SB, Uh SH, Schechter MT, and McCormick AQ. Retinopathy of prematurity-induced blindness: birth weight-specific survival and the new epidemic. Pediatrics 86: 405-412, 1990[Abstract].

26.   Goede, V, Schmidt T, Kimmina S, Kozian D, and Augustin HG. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. Lab Invest 78: 1385-1394, 1998[ISI][Medline].

27.   Grabowski, CT. Embryonic oxygen deficiency---a physiological approach to analysis of teratological mechanisms. Adv Teratol 4: 125-167, 1970.

28.   Grosskreutz, CL, Ande-Apte B, Dupla C, Quinn TP, Terman BI, Zetter B, and D'Amore PA. Vascular endothelial growth factor-induced migration of vascular smooth muscle cells in vitro. Microvasc Res 58: 128-136, 1999[ISI][Medline].

29.   Gustafsson, T, Puntschart A, Kaijser L, Jansson E, and Sundberg CJ. Exercise-induced expression of angiogenesis-related transcription and growth factors in human skeletal muscle. Am J Physiol Heart Circ Physiol 276: H679-H685, 1999[Abstract/Free Full Text].

30.   Huang, LE, Arany Z, Livingston DM, and Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 271: 32253-32259, 1996[Abstract/Free Full Text].

31.   Hunt, TK, Knighton DR, Thakral KK, Goodson WH, and Andrews WS. Studies on inflammation and wound healing: angiogenesis and collagen synthesis stimulated in vivo by resident and activated wound macrophages. Surgery 96: 48-54, 1984[ISI][Medline].

32.   Ikeda, E, Achen MG, Breier G, and Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 270: 19761-19766, 1995[Abstract/Free Full Text].

33.   Kim, KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, and Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362: 841-844, 1993[ISI][Medline].

34.   Knighton, DR, Hunt TK, Scheuenstuhl H, Halliday BJ, Werb Z, and Banda MJ. Oxygen tension regulates the expression of angiogenesis factor by macrophages. Science 221: 1283-1285, 1983[ISI][Medline].

35.   Knighton, DR, Silver IA, and Hunt TK. Regulation of wound-healing angiogenesis-effect of oxygen gradients and inspired oxygen concentration. Surgery 90: 262-270, 1981[ISI][Medline].

36.   Leveen, P, Penky M, Gebre-Medhin S, Swolin B, Larsson E, and Betsholtz C. Mice deficient for PDGF-B show renal, cardiovascular, and hematological abnormalities. Genes Dev 8: 1875-1887, 1994[Abstract].

37.   Levy, AP, Levy NS, and Goldberg MA. Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein. J Biol Chem 271: 25492-25497, 1996[Abstract/Free Full Text].

38.   Levy, AP, Levy NS, and Goldberg MA. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem 271: 2746-2753, 1996[Abstract/Free Full Text].

39.   Lindahl, P, Johansson BR, and Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277: 242-245, 1997[Abstract/Free Full Text].

40.   Losordo, DW, Vale PR, and Isner JM. Gene therapy for myocardial angiogenesis. Am Heart J 138: 132-141, 1999.

41.   Maxwell, PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, and Ratcliffe PJ. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 94: 8104-8109, 1997[Abstract/Free Full Text].

42.   Miao, CY, Zuberbuhler JS, and Zuberbuhler JR. Prevalence of congenital cardiac anomalies at high altitude. J Am Coll Cardiol 12: 224-228, 1988[ISI][Medline].

43.   Michaelson, IC. The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc UK 65: 137-180, 1948.

44.   Orlidge, A, and D'Amore PA. Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells. J Cell Biol 105: 1455-1462, 1987[Abstract].

45.   Plate, KH, Breier G, Weich H, and Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845-848, 1992[ISI][Medline].

46.   Puri, MC, Rossant J, Alitalo K, Bernstein A, and Partanen J. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J 14: 5884-5891, 1995[Abstract].

47.   Richardson, RS, Wagner H, Mudaliar SR, Henry R, Noyszewski EA, and Wagner PD. Human VEGF gene expression in skeletal muscle: effect of acute normoxic and hypoxic exercise. Am J Physiol Heart Circ Physiol 277: H2247-H2252, 1999[Abstract/Free Full Text].

48.   Richardson, RS, Wagner H, Mudaliar SR, Saucedo E, Henry R, and Wagner PD. Exercise adaptation attenuates VEGF gene expression in human skeletal muscle. Am J Physiol Heart Circ Physiol 279: H772-H778, 2000[Abstract/Free Full Text].

49.   Risau, W, and Flamme I. Vasculogenesis. Annu Rev Cell Dev Biol 11: 73-91, 1995[ISI][Medline].

50.   Rivard, A, Berthou-Soulie L, Principe N, Kearney M, Curry C, Branellec D, Semenza GL, and Isner JM. Age-dependent deficit in VEGF expression is associated with reduced hypoxia-inducible factor 1 activity. J Biol Chem 275: 29643-29647, 2000[Abstract/Free Full Text].

51.   Ryan, HE, Lo J, and Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 17: 3005-3015, 1998[Abstract/Free Full Text].

52.   Ryan, HE, Poloni M, McNulty W, Elson D, Gassman M, Arbeit JM, and Johnson RS. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res 60: 4010-4015, 2000[Abstract/Free Full Text].

53.   Sato, TN, Tozawa Y, Deutsch U, Wolburg Buchholz K, Fujiwara Y, Gendron Maguire M, Gridley T, Wolburg H, Risau W, and Qin Y. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376: 70-74, 1995[ISI][Medline].

54.   Sato, Y, and Rifkin DB. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture. J Cell Biol 109: 309-315, 1989[Abstract].

55.   Schaper, W, and Buschmann I. Arteriogenesis, the good and bad of it. Cardiovasc Res 43: 835-837, 1999[ISI][Medline].

56.   Semenza, GL. Transcriptional regulation by hypoxia-inducible factor-1. Trends Cardiovasc Med 6: 151-157, 1966.

57.   Semenza, GL. Surviving ischemia: adaptive responses mediated by hypoxia-inducible factor 1. J Clin Invest 106: 809-812, 2000[Free Full Text].

58.   Shima, DT, Deutsch U, and D'Amore PA. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. FEBS Lett 370: 203-208, 1995[ISI][Medline].

59.   Shultz, A, Lavie L, Hochberg I, Beyar R, Stone T, Skorecki K, Lavie P, Roguin A, and Levy AP. Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation. Circulation 100: 547-552, 1999[Abstract/Free Full Text].

60.   Shweiki, D, Itin A, Soffer D, and Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845, 1992[ISI][Medline].

61.   Shweiki, D, Neeman M, Itin A, and Keshet E. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci USA 92: 768-772, 1995[Abstract].

62.   Simons, M, and Ware JA. Food for starving hearts. Nat Med 2: 519-520, 1996[ISI][Medline].

63.   Soh, EY, Sobhi SA, Wong MG, Meng YG, Siperstein AE, Clark OH, and Duh QY. Thyroid-stimulating hormone promotes the secretion of VEGF in thyroid cancer cell lines. Surgery 120: 944-947, 1996[ISI][Medline].

64.   Speiser, P, Gittelsohn AM, and Patz A. Studies on diabetic retinopathy. III. Influence of diabetes on intramural pericytes. Arch Ophthalmol 80: 332-337, 1968[ISI][Medline].

65.   Stein, I, Neeman M, Shweiki D, Itin A, and Keshet E. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol Cell Biol 15: 5363-5368, 1995[Abstract].

66.   Stein, I, Itin A, Einat P, Skaliter R, Grossman Z, and Keshet E. Translation of VEGF mRNA by internal ribosome entry: implications for translation under hypoxia. Mol Cell Biol 18: 3112-3119, 1998[Abstract/Free Full Text].

67.   Stone, J, Itin A, Alon T, Pe'er J, Gnessin H, Chan Ling T, and Keshet E. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 15: 4738-4747, 1995[Abstract].

68.   Struijker Boudier, HA. Arteriolar and capillary remodeling in hypertension. Drugs 59: 37-40, 1999[Medline].

69.   Suri, C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, and Yancopoulos GD. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87: 1171-1180, 1996[ISI][Medline].

70.   Takeshita, S, Rossow ST, Kearney M, Zheng LP, Bauters C, Bunting S, Ferrara N, Symes JF, and Isner JM. Time course of increased cellular proliferation in collateral arteries after administration of vascular endothelial growth factor in a rabbit model of lower limb vascular insufficiency. Am J Pathol 147: 1649-1660, 1995[Abstract].

71.   Williams, JK, Armstrong ML, and Heistad DD. Vasa vasorum in atherosclerotic coronary arteries: responses to vasoactive stimuli and regression of atherosclerosis. Circ Res 62: 515-523, 1988[Abstract].

72.   Wood, SM, Gleadle JM, Pugh CW, Hankinson O, and Ratcliffe PJ. The role of the aryl hydrocarbon receptor nuclear translocator (ARNT) in hypoxic induction of gene expression. Studies in ARNT-deficient cells. J Biol Chem 271: 15117-15123, 1996[Abstract/Free Full Text].

73.   Zemplenyi, T, Crawford DW, and Cole MA. Adaptation to arterial wall hypoxia demonstrated in vivo with oxygen microcathodes. Atherosclerosis 76: 173-179, 1989[ISI][Medline].

74.   Zhu, H, and Bunn HF. Oxygen sensing and signaling: impact on the regulation of physiologically important genes. Respir Physiol 115: 239-247, 1999[ISI][Medline].


Am J Physiol Cell Physiol 280(6):C1367-C1374
0363-6143/01 $5.00 Copyright © 2001 the American Physiological Society